Furthermore, the NCCN guidelines also recommended somatic testing of KRAS, BRAF, HER2, PALB2, MMR deficiency, and oncogenic gene fusions for pancreatic cancer patients with advanced or metastatic diseases.2 Here, ERBB2 is linked to familial pancreatic carcinoma.